Type: Product
Name: Raxibacumab
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission

Citation: Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, et al. (2014) . PLoS Med 11(4):e1001616.doi:10.1371/journal.pmed.1001616Published: April 8, 2014This is an open-access article, free of all copyright, and may be freely reproduced, ... [Published PLoS medicine - Apr 09 2014]


GSK immunology and rare diseases for US pharmaceuticals vice-president Sheri Mullen said: "We have been collaborating with BARDA for a number of years and raxibacumab is now an important part of the US Government's emergency counter measures against bioterrorism. Through this agreement, we are proud to be helping protect US citizens against such threats."

More Content

All (4) | News (3) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
HIV Monoclonal Antibodies: A New Opportunity to... [Published PLoS medicine - Apr 09 2014]
GSK signs deal with BARDA for anti-anthrax medi... [Published Pharmaceutical Technology - Sep 20 2013]
GSK inks $196 mn pact with BARDA to provide ant... [Published PharmaBiz - Sep 20 2013]
GlaxoSmithKline to supply anthrax treatment to ... [Published Pharmaceutical Business Review - Sep 20 2013]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.